{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-058190","form_type":"8-K","ticker":"ITRMF","cik":"0001659323","company_name":"Iterum Therapeutics plc","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.468872+00:00","generated_at":"2026-06-02T02:24:27.507275+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Iterum submits NDA for oral sulopenem; Q1 net loss narrows to $7.1M, cash runway into 2025","bullets":["NDA resubmitted in April 2024 for oral sulopenem; FDA action expected early Q4 2024.","Cash, equivalents & short-term investments $18.2M at March 31, 2024; ATM raised $7.2M in Q1.","Net loss $7.1M in Q1 2024 vs $9.9M in Q1 2023; non-GAAP net loss $5.8M vs $7.4M.","R&D expenses fell to $4.0M from $6.4M as REASSURE trial enrollment completed in October 2023.","Cash runway extended into 2025, including through expected PDUFA date in early Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-058190","json":"https://secwatch.observer/filing/0000950170-24-058190.json","markdown":"https://secwatch.observer/filing/0000950170-24-058190.md","text":"https://secwatch.observer/filing/0000950170-24-058190.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659323/000095017024058190/0000950170-24-058190-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659323/000095017024058190/itrm-20240513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:24:27.507275+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1d9d5a59549aeb20c0d0e4df15237728d6480831","claim":"Iterum Therapeutics plc reported first quarter ended March 31, 2024 results: net income $7.1 million.","evidence_excerpt":"iterum Therapeutics plc issued a press release announcing its financial results for the first quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1659323/000095017024058190/0000950170-24-058190-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"$7.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}